Pub Date : 2024-11-06eCollection Date: 2024-01-01DOI: 10.3389/fddev.2024.1456654
R R C New, M Bogus, G N Travers, U Hahn, A Vaiceliunaite, M Burnet, J H Wang, H Wen
GLP-1 receptor agonists ((GLP-1 RAs) are currently receiving a lot of attention because of their impact in diabetes, weight loss and other areas. While GLP-1 RAs in injectable form are highly efficacious, further work is required to develop oral versions which can deliver these peptides efficiently without requiring use of excessively high doses. This paper describes the ability of an oral peptide delivery formulation, Axcess™, to enhance uptake of GLP-1 receptor agonists via the intestine, resulting in changes in insulin and glucose blood levels indicative of biopotencies of 9% for exendin-4 and 14.8% for semaglutide in preclinical models. The route of delivery suggests that the peptides will be able to interact with the GLP-1 receptors on the vagal afferents of the intestine, as is the case for native GLP-1 in healthy individuals. GLP-1 receptor agonists administered via this route will be a valuable addition to the therapeutic modalities available for treatment of diabetes and obesity.
{"title":"Glucagon-like peptide-1 receptor agonists for treatment of diabetes and obesity: advantage of oral delivery.","authors":"R R C New, M Bogus, G N Travers, U Hahn, A Vaiceliunaite, M Burnet, J H Wang, H Wen","doi":"10.3389/fddev.2024.1456654","DOIUrl":"10.3389/fddev.2024.1456654","url":null,"abstract":"<p><p>GLP-1 receptor agonists ((GLP-1 RAs) are currently receiving a lot of attention because of their impact in diabetes, weight loss and other areas. While GLP-1 RAs in injectable form are highly efficacious, further work is required to develop oral versions which can deliver these peptides efficiently without requiring use of excessively high doses. This paper describes the ability of an oral peptide delivery formulation, Axcess™, to enhance uptake of GLP-1 receptor agonists via the intestine, resulting in changes in insulin and glucose blood levels indicative of biopotencies of 9% for exendin-4 and 14.8% for semaglutide in preclinical models. The route of delivery suggests that the peptides will be able to interact with the GLP-1 receptors on the vagal afferents of the intestine, as is the case for native GLP-1 in healthy individuals. GLP-1 receptor agonists administered via this route will be a valuable addition to the therapeutic modalities available for treatment of diabetes and obesity.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"4 ","pages":"1456654"},"PeriodicalIF":0.0,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363265/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-15eCollection Date: 2024-01-01DOI: 10.3389/fddev.2024.1400937
Szilvia Veszelka, Malgorzata Burek, Sarah Ann Thomas
{"title":"Editorial: Women in CNS drug delivery: 2022-2024.","authors":"Szilvia Veszelka, Malgorzata Burek, Sarah Ann Thomas","doi":"10.3389/fddev.2024.1400937","DOIUrl":"10.3389/fddev.2024.1400937","url":null,"abstract":"","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"4 ","pages":"1400937"},"PeriodicalIF":0.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363288/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-16eCollection Date: 2024-01-01DOI: 10.3389/fddev.2024.1458009
Karolina Dziemidowicz, Mark Meszarik, Jacopo Piovesan, Mazna A Almatroudi, Gareth R Williams, Sudaxshina Murdan
Fungal infections, though affecting healthcare globally, receive insufficient attention in clinical and academic settings. Invasive fungal infections, particularly caused by combat wounds, have been identified as a critical threat by the US Department of Defense. Monotherapy with traditional antifungals is often insufficient, and so combination therapies are explored to enhance treatment efficacy. However, systemic combination treatments can result in severe adverse effects, suggesting the need for localised delivery systems, such as drug-loaded electrospun patches, to administer antifungals directly to the infection site. This proof-of-concept study hypothesised that dual amorolfine and terbinafine therapy slowly releasing from electrospun patches would be an effective way of eradicating Candida albicans when the patch was applied directly to the fungal colony. The feasibility of creating electrospun materials loaded with amorolfine and terbinafine for combination antifungal therapy was investigated. Electrospinning was used to fabricate polycaprolactone (PCL) patches with varying drug loadings (2.5%, 5%, and 10% w/w) of amorolfine and terbinafine either individually or in combination. The incorporation of both drugs in the fibres was confirmed, with the drugs predominantly in an amorphous state. Results showed that combination therapy patches had a significantly greater and prolonged antifungal effect compared to monotherapy patches, with larger zones of inhibition and sustained efficacy over at least 7 days. This study therefore demonstrates that PCL-based electrospun patches containing amorolfine and terbinafine provide superior antifungal activity against C. albicans compared to monotherapy patches. This approach could lower required drug doses, reducing adverse effects, and enhance patient compliance due to prolonged drug release, leading to more effective antifungal therapy.
{"title":"Electrospun patches to deliver combination drug therapy for fungal infections.","authors":"Karolina Dziemidowicz, Mark Meszarik, Jacopo Piovesan, Mazna A Almatroudi, Gareth R Williams, Sudaxshina Murdan","doi":"10.3389/fddev.2024.1458009","DOIUrl":"10.3389/fddev.2024.1458009","url":null,"abstract":"<p><p>Fungal infections, though affecting healthcare globally, receive insufficient attention in clinical and academic settings. Invasive fungal infections, particularly caused by combat wounds, have been identified as a critical threat by the US Department of Defense. Monotherapy with traditional antifungals is often insufficient, and so combination therapies are explored to enhance treatment efficacy. However, systemic combination treatments can result in severe adverse effects, suggesting the need for localised delivery systems, such as drug-loaded electrospun patches, to administer antifungals directly to the infection site. This proof-of-concept study hypothesised that dual amorolfine and terbinafine therapy slowly releasing from electrospun patches would be an effective way of eradicating <i>Candida albicans</i> when the patch was applied directly to the fungal colony. The feasibility of creating electrospun materials loaded with amorolfine and terbinafine for combination antifungal therapy was investigated. Electrospinning was used to fabricate polycaprolactone (PCL) patches with varying drug loadings (2.5%, 5%, and 10% w/w) of amorolfine and terbinafine either individually or in combination. The incorporation of both drugs in the fibres was confirmed, with the drugs predominantly in an amorphous state. Results showed that combination therapy patches had a significantly greater and prolonged antifungal effect compared to monotherapy patches, with larger zones of inhibition and sustained efficacy over at least 7 days. This study therefore demonstrates that PCL-based electrospun patches containing amorolfine and terbinafine provide superior antifungal activity against <i>C. albicans</i> compared to monotherapy patches. This approach could lower required drug doses, reducing adverse effects, and enhance patient compliance due to prolonged drug release, leading to more effective antifungal therapy.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"4 ","pages":"1458009"},"PeriodicalIF":0.0,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363251/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144980999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-13eCollection Date: 2024-01-01DOI: 10.3389/fddev.2024.1364037
Marco Grados, Mona Salehi, Aida Lotfi, Sagar Dua, Isabella Xie
Psychotropics are currently developed and marketed with a limited understanding of their mechanism of action. The notion that protein kinase C (PKC) activity is highly relevant to learning and memory function stems from experiments in the 1980s, which associated protein kinase alpha (pka) and pkc to animal models of associative learning, opening an area of exploration for psychotropic development. The PKC family consists of several isoforms, including PKC alpha, beta1, beta1, gamma, delta and epsilon among others. In particular, PKC gamma (PRKCG) is highly brain-expressed and is singled out as a candidate for modulation in psychiatric illness. With hundreds of identified substrates, PRKCG affects multiple pathways relevant for regulation of neuronal health. In this review, converging lines of evidence are presented in the context of psychotropic drug action, which point to downregulation of PKC activity as a potential common mechanism across several psychiatric disorders. Using this mechanism through more targeted psychotropic action may then be used to develop agents that further ameliorate psychiatric symptom expression. Psychotropics including fluoxetine, tricyclics, lithium, valproate, ketamine and others are explored in relation to their effect of PKC, finding that across all drugs examined, a downregulation with chronic-but not acute-use constitutes their putative effect in ameliorating symptoms. This effect is compounded by findings that suggest that PKCs, and PRKCG in particular, promote neuroplastic effects by their downregulation. This effect is in contrast to PKC activators, which have been used in neurodegenerative disorders such as Alzheimer's disease. Cross-disorder mechanisms need to continue to be explored in neuropsychiatric illness and targeted treatments developed in turn to address treatment-resistant conditions.
{"title":"A selective review of inhibitors of protein kinase C gamma: a neuroplasticity-related common pathway for psychiatric illness.","authors":"Marco Grados, Mona Salehi, Aida Lotfi, Sagar Dua, Isabella Xie","doi":"10.3389/fddev.2024.1364037","DOIUrl":"10.3389/fddev.2024.1364037","url":null,"abstract":"<p><p>Psychotropics are currently developed and marketed with a limited understanding of their mechanism of action. The notion that protein kinase C (PKC) activity is highly relevant to learning and memory function stems from experiments in the 1980s, which associated protein kinase alpha (pka) and pkc to animal models of associative learning, opening an area of exploration for psychotropic development. The PKC family consists of several isoforms, including PKC alpha, beta1, beta1, gamma, delta and epsilon among others. In particular, PKC gamma (PRKCG) is highly brain-expressed and is singled out as a candidate for modulation in psychiatric illness. With hundreds of identified substrates, PRKCG affects multiple pathways relevant for regulation of neuronal health. In this review, converging lines of evidence are presented in the context of psychotropic drug action, which point to downregulation of PKC activity as a potential common mechanism across several psychiatric disorders. Using this mechanism through more targeted psychotropic action may then be used to develop agents that further ameliorate psychiatric symptom expression. Psychotropics including fluoxetine, tricyclics, lithium, valproate, ketamine and others are explored in relation to their effect of PKC, finding that across all drugs examined, a downregulation with chronic-but not acute-use constitutes their putative effect in ameliorating symptoms. This effect is compounded by findings that suggest that PKCs, and PRKCG in particular, promote neuroplastic effects by their downregulation. This effect is in contrast to PKC activators, which have been used in neurodegenerative disorders such as Alzheimer's disease. Cross-disorder mechanisms need to continue to be explored in neuropsychiatric illness and targeted treatments developed in turn to address treatment-resistant conditions.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"4 ","pages":"1364037"},"PeriodicalIF":0.0,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363335/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-10eCollection Date: 2024-01-01DOI: 10.3389/fddev.2024.1441956
Zerelda Esquer Garrigos, John N Catanzaro, Daniel Deegan, Ji Zhang, M Rizwan Sohail
The risk of infection remains a significant concern with cardiovascular implantable electronic devices, necessitating the development of new strategies. This study explores the efficacy of a novel antibiotic-eluting biologic envelope designed to mitigate infection risk through localized antibiotic delivery while preserving the regenerative properties of biological matrix. Antibiotics, rifampin and minocycline, are released through polymer discs, ensuring extended drug release. Utilizing an established model of infection in a New Zealand White rabbit, the study assessed performance against Gram-positive bacterial strains, including common pathogens such as Staphylococcus aureus and S. epidermidis associated with CIED infections, and Gram-negative bacterial strains. Results demonstrated strong antibacterial activity, achieving complete eradication of bacterial colonies and greater than 6-log reductions in colonization for all strains. Pharmacokinetic analysis revealed sustained local antibiotic concentrations at the implantation site for up to 14 days, with minimal systemic exposure, demonstrating the advantages of localized drug delivery. Health outcomes in the antibiotic bioenvelope group were significantly improved, with no signs of infection or abnormal body temperatures, in contrast to the control group. Macroscopic examinations post-necropsy confirmed the absence of infection at the implantation sites of animals receiving the antibiotic bioenvelope. The combination of localized antibiotic delivery in a regenerative matrix positions the antibiotic bioenvelope as a promising solution for preventing CIED-related infections.
{"title":"Preclinical evaluation of a novel antibiotic-eluting BioEnvelope for CIED infection prevention.","authors":"Zerelda Esquer Garrigos, John N Catanzaro, Daniel Deegan, Ji Zhang, M Rizwan Sohail","doi":"10.3389/fddev.2024.1441956","DOIUrl":"10.3389/fddev.2024.1441956","url":null,"abstract":"<p><p>The risk of infection remains a significant concern with cardiovascular implantable electronic devices, necessitating the development of new strategies. This study explores the efficacy of a novel antibiotic-eluting biologic envelope designed to mitigate infection risk through localized antibiotic delivery while preserving the regenerative properties of biological matrix. Antibiotics, rifampin and minocycline, are released through polymer discs, ensuring extended drug release. Utilizing an established model of infection in a New Zealand White rabbit, the study assessed performance against Gram-positive bacterial strains, including common pathogens such as <i>Staphylococcus aureus</i> and <i>S. epidermidis</i> associated with CIED infections, and Gram-negative bacterial strains. Results demonstrated strong antibacterial activity, achieving complete eradication of bacterial colonies and greater than 6-log reductions in colonization for all strains. Pharmacokinetic analysis revealed sustained local antibiotic concentrations at the implantation site for up to 14 days, with minimal systemic exposure, demonstrating the advantages of localized drug delivery. Health outcomes in the antibiotic bioenvelope group were significantly improved, with no signs of infection or abnormal body temperatures, in contrast to the control group. Macroscopic examinations post-necropsy confirmed the absence of infection at the implantation sites of animals receiving the antibiotic bioenvelope. The combination of localized antibiotic delivery in a regenerative matrix positions the antibiotic bioenvelope as a promising solution for preventing CIED-related infections.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"4 ","pages":"1441956"},"PeriodicalIF":0.0,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363317/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-15eCollection Date: 2024-01-01DOI: 10.3389/fddev.2024.1416737
Katarzyna Karpinska, Lin Li, Tao Wang
RNA therapy is a rapidly expanding field and has great promise in achieving targeted gene silencing and contributing to personalized medicine. However, the delivery of RNA molecules into targeted organs or cells is still challenging. To overcome this hurdle, a number of nanocarriers with pros and cons have been developed. This study was designed to develop a simple and cost-effective approach to functionalize biodegradable magnetic iron nanoparticles (MNPs) for cell-specific siRNA delivery. MNPs were synthesized based on co-precipitation and further functionalized with sodium citrate and polyethyleneimine (PEI) followed by material characterization using TEM, FTIR, and Zeta potential. The citrate and PEI-coated MNPs were further conjugated with CD31 antibody and complexed with siRNA using a linker-free approach. siRNA-loaded MNPs successfully knocked down the expression of GAPDH in human endothelial cells (ECs) and NOTCH3 in human vascular smooth muscle cells (VSMCs). In an EC and VSMC co-culture system under shear stress to mimic blood flow, siRNA and CD31 conjugated MNPs specifically targeted and delivered siRNA into the ECs. Our approach represents a versatile platform that could be adopted for targeted general siRNA delivery.
{"title":"Dual conjugation of magnetic nanoparticles with antibodies and siRNA for cell-specific gene silencing in vascular cells.","authors":"Katarzyna Karpinska, Lin Li, Tao Wang","doi":"10.3389/fddev.2024.1416737","DOIUrl":"10.3389/fddev.2024.1416737","url":null,"abstract":"<p><p>RNA therapy is a rapidly expanding field and has great promise in achieving targeted gene silencing and contributing to personalized medicine. However, the delivery of RNA molecules into targeted organs or cells is still challenging. To overcome this hurdle, a number of nanocarriers with pros and cons have been developed. This study was designed to develop a simple and cost-effective approach to functionalize biodegradable magnetic iron nanoparticles (MNPs) for cell-specific siRNA delivery. MNPs were synthesized based on co-precipitation and further functionalized with sodium citrate and polyethyleneimine (PEI) followed by material characterization using TEM, FTIR, and Zeta potential. The citrate and PEI-coated MNPs were further conjugated with CD31 antibody and complexed with siRNA using a linker-free approach. siRNA-loaded MNPs successfully knocked down the expression of <i>GAPDH</i> in human endothelial cells (ECs) and <i>NOTCH3</i> in human vascular smooth muscle cells (VSMCs). In an EC and VSMC co-culture system under shear stress to mimic blood flow, siRNA and CD31 conjugated MNPs specifically targeted and delivered siRNA into the ECs. Our approach represents a versatile platform that could be adopted for targeted general siRNA delivery.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"4 ","pages":"1416737"},"PeriodicalIF":0.0,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363332/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144980984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-08DOI: 10.3389/fddev.2024.1436842
M. Puccetti, Claudio Costantini, A. Schoubben, S. Giovagnoli, Maurizio Ricci
This review article explores the potential of engineering antigen-presenting cells (APCs) for the immunotherapy of autoimmune diseases. It discusses various strategies for modifying APCs to induce antigen-specific tolerance, thereby mitigating autoimmune responses. The review covers recent advancements in APC engineering techniques, including genetic modification and nanoparticle-based approaches, and evaluates their efficacy in preclinical models and clinical trials. Additionally, challenges and future directions for the development of APC-based immunotherapies for autoimmunity – and other forms of cell-based immunotherapy – are discussed. Along this direction, this review (i) describes various strategies for engineering APCs, including genetic modification, nanoparticle delivery systems, and ex vivo manipulation techniques; (ii) discusses the selection of target antigens and the design of APC-based immunotherapies, and (iii) reviews preclinical models used to evaluate the efficacy and safety of engineered APCs in inducing antigen-specific tolerance.
{"title":"Strategies and delivery systems for cell-based therapy in autoimmunity","authors":"M. Puccetti, Claudio Costantini, A. Schoubben, S. Giovagnoli, Maurizio Ricci","doi":"10.3389/fddev.2024.1436842","DOIUrl":"https://doi.org/10.3389/fddev.2024.1436842","url":null,"abstract":"This review article explores the potential of engineering antigen-presenting cells (APCs) for the immunotherapy of autoimmune diseases. It discusses various strategies for modifying APCs to induce antigen-specific tolerance, thereby mitigating autoimmune responses. The review covers recent advancements in APC engineering techniques, including genetic modification and nanoparticle-based approaches, and evaluates their efficacy in preclinical models and clinical trials. Additionally, challenges and future directions for the development of APC-based immunotherapies for autoimmunity – and other forms of cell-based immunotherapy – are discussed. Along this direction, this review (i) describes various strategies for engineering APCs, including genetic modification, nanoparticle delivery systems, and ex vivo manipulation techniques; (ii) discusses the selection of target antigens and the design of APC-based immunotherapies, and (iii) reviews preclinical models used to evaluate the efficacy and safety of engineered APCs in inducing antigen-specific tolerance.","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"14 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141927430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-18eCollection Date: 2024-01-01DOI: 10.3389/fddev.2024.1452132
Clara Schweiker, Sergej Zankovic, Anna Baghnavi, Dirk Velten, Hagen Schmal, Ralf Thomann, Michael Seidenstuecker
[This corrects the article DOI: 10.3389/fddev.2024.1407304.].
[这更正了文章DOI: 10.3389/fddev.2024.1407304.]。
{"title":"Corrigendum: Core-shell 3D printed biodegradable calcium phosphate cement - Alginate scaffolds for possible bone regeneration applications.","authors":"Clara Schweiker, Sergej Zankovic, Anna Baghnavi, Dirk Velten, Hagen Schmal, Ralf Thomann, Michael Seidenstuecker","doi":"10.3389/fddev.2024.1452132","DOIUrl":"10.3389/fddev.2024.1452132","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/fddev.2024.1407304.].</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"4 ","pages":"1452132"},"PeriodicalIF":0.0,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144980969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Due to the inherent risk of a further pandemic influenza outbreak, there is a need and growing interest in investigating combinations of prophylactic vaccines and novel adjuvants, particularly to achieve antigen dose sparing and improved immunogenicity. Influenza is a highly variable virus, where the specific vaccine target is constantly changing, representing a major challenge to influenza vaccine development. Currently, commercial inactivated influenza vaccines have a poor CD8+ T response, which impacts cross-reactivity and the duration of response. Adjuvanted influenza vaccines can increase immune responses, thereby achieving better protection and cross-reactivity to help contain the spread of the disease. An early exploration of a hybrid cholesterol-PLGA nanoparticle delivery system containing the saponin tomatine and a NOD2 (nucleotide-binding oligomerization domain 2) agonist called SG101 was conducted. This combination was preliminarily evaluated for its ability to induce cellular immunity when combined with whole inactivated virus (WIV) influenza vaccine. After the adjuvants were manufactured using a single emulsion process, two formulations with different drug loadings were selected and physico-chemically characterized, showing sizes between 224 ± 32 and 309 ± 45 nm and different morphologies. After ensuring the lack of in vitro toxicity and hemolytic activity, a pilot in vivo assay evaluated the hybrid nanoparticle formulation for its ability to induce humoral and cellular immunity when combined with whole inactivated virus (WIV) H5N1 influenza vaccine by intramuscular administration in mice. Hemagglutinin inhibition (HAI) titers for adjuvanted groups showed no significant difference compared to the group vaccinated with the antigen alone. It was similar for CD4+ and CD8+ T cell responses, although the high drug loading formulation induced higher titers of IFNγ-positive CD8+ T cells. These proof-of-concept results encourage further investigations to develop the hybrid formulation with increased or different loading ratios, to investigate manufacturing optimization, and to evaluate the role of the individual immunostimulatory compounds in immune responses.
由于流感大流行爆发的内在风险,人们需要研究预防性疫苗和新型佐剂的组合,特别是实现抗原剂量稀释和提高免疫原性,而且这种研究的兴趣日益浓厚。流感是一种高度易变的病毒,特定的疫苗靶点不断变化,这对流感疫苗的开发是一个重大挑战。目前,商用灭活流感疫苗的 CD8+ T 反应较差,影响交叉反应和反应持续时间。添加佐剂的流感疫苗可以提高免疫反应,从而获得更好的保护和交叉反应,有助于遏制疾病的传播。我们对含有皂素番茄碱和名为 SG101 的 NOD2(核苷酸结合寡聚化结构域 2)激动剂的胆固醇-PLGA 混合纳米颗粒递送系统进行了早期探索。初步评估了这种组合与全灭活病毒(WIV)流感疫苗结合使用时诱导细胞免疫的能力。在使用单一乳液工艺制造佐剂后,选择了两种不同药物载量的制剂,并对其进行了物理化学表征,结果显示这两种制剂的尺寸介于 224 ± 32 nm 和 309 ± 45 nm 之间,形态各异。在确保无体外毒性和溶血活性后,一项试验性体内试验评估了混合纳米颗粒配方与全灭活病毒(WIV)H5N1 流感疫苗结合后在小鼠体内肌肉注射诱导体液免疫和细胞免疫的能力。添加佐剂组的血凝素抑制滴度(HAI)与单独接种抗原组相比无显著差异。CD4+ 和 CD8+ T 细胞反应相似,但高药物载量配方诱导的 IFNγ 阳性 CD8+ T 细胞滴度更高。这些概念验证结果鼓励人们进一步研究开发增加或改变负载率的混合制剂,研究生产优化,并评估单个免疫刺激化合物在免疫反应中的作用。
{"title":"Preliminary results on novel adjuvant combinations suggest enhanced immunogenicity of whole inactivated pandemic influenza vaccines","authors":"Allegra Peletta, Aurélie Marmy, Samo Guzelj, Alcidia Ramos Barros, Ž. Jakopin, Gerrit Borchard","doi":"10.3389/fddev.2024.1382266","DOIUrl":"https://doi.org/10.3389/fddev.2024.1382266","url":null,"abstract":"Due to the inherent risk of a further pandemic influenza outbreak, there is a need and growing interest in investigating combinations of prophylactic vaccines and novel adjuvants, particularly to achieve antigen dose sparing and improved immunogenicity. Influenza is a highly variable virus, where the specific vaccine target is constantly changing, representing a major challenge to influenza vaccine development. Currently, commercial inactivated influenza vaccines have a poor CD8+ T response, which impacts cross-reactivity and the duration of response. Adjuvanted influenza vaccines can increase immune responses, thereby achieving better protection and cross-reactivity to help contain the spread of the disease. An early exploration of a hybrid cholesterol-PLGA nanoparticle delivery system containing the saponin tomatine and a NOD2 (nucleotide-binding oligomerization domain 2) agonist called SG101 was conducted. This combination was preliminarily evaluated for its ability to induce cellular immunity when combined with whole inactivated virus (WIV) influenza vaccine. After the adjuvants were manufactured using a single emulsion process, two formulations with different drug loadings were selected and physico-chemically characterized, showing sizes between 224 ± 32 and 309 ± 45 nm and different morphologies. After ensuring the lack of in vitro toxicity and hemolytic activity, a pilot in vivo assay evaluated the hybrid nanoparticle formulation for its ability to induce humoral and cellular immunity when combined with whole inactivated virus (WIV) H5N1 influenza vaccine by intramuscular administration in mice. Hemagglutinin inhibition (HAI) titers for adjuvanted groups showed no significant difference compared to the group vaccinated with the antigen alone. It was similar for CD4+ and CD8+ T cell responses, although the high drug loading formulation induced higher titers of IFNγ-positive CD8+ T cells. These proof-of-concept results encourage further investigations to develop the hybrid formulation with increased or different loading ratios, to investigate manufacturing optimization, and to evaluate the role of the individual immunostimulatory compounds in immune responses.","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"6 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141640751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-05DOI: 10.3389/fddev.2024.1433453
Sarah F. Hathcock, Hallie E. Knight, Emma G. Tong, Alexandra E. Meyer, Henry D. Mauser, Nadine Vollmuth, Brandon J. Kim
The blood-brain barrier (BBB) is comprised of specialized brain endothelial cells (BECs) that contribute to maintaining central nervous system (CNS) homeostasis. BECs possess properties such as an array of multi-drug efflux transporters that eject various drugs and toxins, preventing their entry into the CNS. Together, it is estimated that these efflux transporters can eject up to 98% of known xenobiotic compounds. P-glycoprotein (P-gp) is a promiscuous efflux transporter at the BBB and can efflux up to 90 various substrates, representing a major hurdle in CNS drug delivery for therapeutic interventions. This necessitates the study of P-gp to discover drugs that are non-substrates of P-gp as well as to identify novel P-gp inhibitors. Here we report the generation of P-gp overexpressing BECs under the endogenous promoter control that could be used in the screening of P-gp substrates. These cells could provide utility in the design of drugs or identification of novel inhibitors.
{"title":"Induction of P-glycoprotein overexpression in brain endothelial cells as a model to study blood-brain barrier efflux transport","authors":"Sarah F. Hathcock, Hallie E. Knight, Emma G. Tong, Alexandra E. Meyer, Henry D. Mauser, Nadine Vollmuth, Brandon J. Kim","doi":"10.3389/fddev.2024.1433453","DOIUrl":"https://doi.org/10.3389/fddev.2024.1433453","url":null,"abstract":"The blood-brain barrier (BBB) is comprised of specialized brain endothelial cells (BECs) that contribute to maintaining central nervous system (CNS) homeostasis. BECs possess properties such as an array of multi-drug efflux transporters that eject various drugs and toxins, preventing their entry into the CNS. Together, it is estimated that these efflux transporters can eject up to 98% of known xenobiotic compounds. P-glycoprotein (P-gp) is a promiscuous efflux transporter at the BBB and can efflux up to 90 various substrates, representing a major hurdle in CNS drug delivery for therapeutic interventions. This necessitates the study of P-gp to discover drugs that are non-substrates of P-gp as well as to identify novel P-gp inhibitors. Here we report the generation of P-gp overexpressing BECs under the endogenous promoter control that could be used in the screening of P-gp substrates. These cells could provide utility in the design of drugs or identification of novel inhibitors.","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":" 21","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141677182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}